temozolomide
Orphan DrugFDA Approved, EMA Approved
Description
Temozolomide is an oral alkylating agent used in the treatment of brain tumors including glioblastoma multiforme and anaplastic astrocytoma. It is also used for certain pediatric brain tumors and embryonal tumors of the central nervous system. The drug methylates DNA, leading to cell death in rapidly dividing cancer cells.
Indications & Therapeutic Use
glioblastoma multiforme, anaplastic astrocytoma, embryonal brain tumors, medulloblastoma
Linked Diseases:
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
temozolomide
| Generic Name | temozolomide |
| Brands | 1 brand available |
| Active Ingredient | temozolomide |
| Drug Class | glioblastoma multiforme |
| Manufacturer | Merck/Sun Pharmaceutical |
| Dosage Forms | oral capsule, 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mg |
| Medical Code | L01AX03 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00002840 |
| Countries | 10 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations11 Validated Nodes